90 results
8-K
EX-99.1
MAIA
MAIA Biotechnology Inc
6 Jun 24
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
2:57pm
(THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments
8-K
EX-99.3
MAIA
MAIA Biotechnology Inc
4 Jun 24
Regulation FD Disclosure
4:06pm
damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS
8-K
EX-99.1
MAIA
MAIA Biotechnology Inc
4 Jun 24
Regulation FD Disclosure
4:06pm
Disease (PD) Death 20 patients in 3L; Withdrawal 4 patients 4L+ Others 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Months … Stable Disease (SD) Partial Response (PR) 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Progressive Disease (PD) PFS (3L) = OS (3L) = Death Months 2,3 4 5.8
8-K
EX-99.1
MAIA
MAIA Biotechnology Inc
3 Jun 24
Regulation FD Disclosure
4:05pm
without permission from ASCO® or the author of this poster Treatment Follow-Up Stable Disease (SD) Partial Response (PR) Progressive Disease (PD) Death … Withdrawal Others Treatment Follow-Up Stable Disease (SD) Partial Response (PR) Progressive Disease (PD) Death Withdrawal Others Treatment Follow-Up
8-K
EX-99.2
MAIA
MAIA Biotechnology Inc
3 Jun 24
Regulation FD Disclosure
4:05pm
) Progressive Disease (PD) Death Withdrawal Others *Includes all patients with ≥1 post-baseline response assessment.
EFFICACY Third-Line Patients receiving … Stable Disease (SD) Partial Response (PR) Progressive Disease (PD) Death Withdrawal Others Note: This is a snapshot including ongoing subjects and data
8-K
EX-99.1
2bviw txbl
8 Mar 24
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
4:15pm
8-K
EX-99.2
rthqwti4i1x eh
8 Mar 24
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
4:15pm
8-K
EX-99.1
298nesguz2qryxwp1k0b
27 Feb 24
MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
5:23pm
8-K
EX-99.1
zmy1pt6mslm92y7rq
23 Feb 24
MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
4:17pm
424B5
mts sdagl
14 Feb 24
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.1
i4zblhdoxcpugcb1
30 Jan 24
MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds
9:00am
8-K
EX-99.1
z7s6k 172hx0gvdghoo
18 Jan 24
MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024
6:01am
8-K
EX-99.1
ujpeyupxjri
21 Dec 23
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
7:00am
424B5
qbuyww43sds0 pu
17 Nov 23
Prospectus supplement for primary offering
9:06am
8-K
EX-99.1
g69fkhb
13 Nov 23
Other Events
6:07am
8-K
EX-99.1
por2h 3oey
7 Nov 23
MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO
8:05am